市场调查报告书
商品编码
1451500
2024-2032 年组织工程市场报告(按类型、应用、最终用户和地区)Tissue Engineering Market Report by Type, Application, End User, and Region 2024-2032 |
2023年全球组织工程市场规模达180亿美元。展望未来, IMARC Group预计到2032年市场规模将达到484亿美元,2024-2032年复合年增长率(CAGR)为11.3%。
组织工程(TE)是一门生物医学工程学科,它将细胞、支架和生物活性分子结合成功能组织。它应用生命科学和工程学的原理来开发生物替代品来恢復、改善、维持或替换不同类型的组织或器官。它为移植、外科重建手术和其他用于修復受损组织的机械装置提供了有效的替代方案。因此,组织工程在许多医疗应用中迅速获得关注,包括烧伤治疗、神经病学、伤口护理、骨科、肌肉骨骼、心血管和泌尿科产品。如今,研究人员正专注于开发用于皮肤替代的生物材料,以满足对相对便宜且易于获得的皮肤替代产品不断增长的需求。
组织工程程序已被证明可以有效治疗组织的不可逆损伤。这导致再生医学和 TE 手术的需求显着增加,这是推动市场成长的主要因素。除此之外,致命道路事故和外伤发生率的上升,以及患者对骨植入物的需求不断增长,都增加了产品需求。此外,由于久坐的生活习惯、人口老化和不健康饮食,糖尿病、癌症、肥胖和心血管疾病等慢性病的广泛流行正在促进市场成长。此外,三维(3D)组织工程领域的技术进步,例如器官晶片技术、以干细胞取代胚胎细胞以及使用3D生物列印机有效设计体外植入物,正在提供利润丰厚的市场机会。此外,多项产品创新以及政府资助和私人对研发(R&D)活动的投资不断增加正在推动市场成长。其他因素,包括替换和重建手术数量的增加、消费者医疗保健支出的增加以及整形手术需求的激增,也创造了积极的市场前景。
The global tissue engineering market size reached US$ 18.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 48.4 Billion by 2032, exhibiting a growth rate (CAGR) of 11.3% during 2024-2032.
Tissue engineering (TE) is a biomedical engineering discipline that combines cells, scaffolds, and biologically active molecules into functional tissues. It applies the principles of life sciences and engineering to develop biological substitutes to restore, improve, maintain, or replace different types of tissues or organs. It provides efficient alternatives to transplants, surgical reconstruction procedures, and other mechanical devices that are used to repair damaged tissues. As a result, tissue engineering is rapidly gaining traction in numerous medical applications, including burn treatment, neurology, wound care, orthopedic, musculoskeletal, cardiovascular, and urological products. Nowadays, researchers are focusing on developing biomaterials for skin substitution to meet the growing demand for relatively cheaper and easily available skin replacement products.
Tissue engineering procedures have proven effective in treating irreversible damage to tissues. This has led to a significant increase in the demand for regenerative medicines and TE procedures, which represents the primary factor driving the market growth. Besides this, the rising incidences of fatal road accidents and trauma injuries, along with the growing need for bone implants among patients, are augmenting the product demand. Additionally, the widespread prevalence of chronic diseases, such as diabetes, cancer, obesity and cardiovascular disorders, due to sedentary lifestyle habits, aging population and unhealthy diets, is catalyzing the market growth. Furthermore, technological advancements in the field of three-dimensional (3D) tissue engineering, such as organ-on-a-chip technology, replacement of embryo cells with stem cells, and use of 3D bioprinters to design in vitro implants efficiently, are offering lucrative opportunities to the market. Moreover, several product innovations, and the increasing government funding and private investments in research and development (R&D) activities are propelling the market growth. Other factors, including the growing number of replacements and reconstructive surgeries, rising consumer healthcare expenditure, and surging demand for plastic surgeries, are also creating a positive market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global tissue engineering market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, application and end user.
Synthetic Scaffold Material
Biologically Derived Scaffold Material
Others
Orthopedics and Musculoskeletal
Neurology
Cardiovascular
Skin and Integumentary
Dental
Others
Hospitals and Clinics
Ambulatory Facilities
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., B. Braun Melsungen AG, Baxter International Inc, Becton, Dickinson and Company, Integra LifeSciences Corporation, Organogenesis Holdings Inc, RTI Surgical, Smith & Nephew plc, Stryker Corporation, Vericel Corporation and Zimmer Biomet.